Theodore Martinot

Dr. Theodore Martinot joined FogPharma in September 2021 as Vice President of Pharmaceutical Development. In this role, he will enable the supply of Helicon™ peptides drug substances and drug products to the clinic and help build a platform capable of empowering new modality Helicon drug discovery.

Dr. Martinot brings over fifteen years of leadership experience in drug development from the preclinical phase to New Drug applications and has worked on successful drugs including Incivek (telaprevir) and Copiktra (duvelisib). Throughout his career, Dr. Martinot has demonstrated a continuous passion and drive to push the boundaries of scientific achievement.

Prior to joining FogPharma, Dr. Martinot was a Senior Director of Chemistry at Infinity Pharmaceuticals where he worked to establish a commercial-ready process for the manufacture of eganelisib and led preclinical and clinical collaboration discussions for the drug candidate. Prior to his most recent role at Infinity, he was a member of the Discovery Process Chemistry group at Merck in Boston and contributed to multiple programs in oncology and neuroscience. Before his move to Merck, Dr. Martinot held positions of increasing responsibility at Infinity and started his career at Vertex Pharmaceuticals.